Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archdermatol.2010.405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr Hasan Sadikin Hospital, Bandung, West Java, Indonesia.
Epidermal growth factor receptor inhibitors (EGFRI) are biological factors used in several types of cancer, including non-small-cell lung cancers (NSCLC). One of the EGFR inhibitors that has been approved for NSCLC is afatinib. Dermatologic adverse events are the most commonly reported and may impair the patient's compliance to the therapy as it causes aesthetic discomfort and significantly impact the patient's quality of life.
View Article and Find Full Text PDFEGFR-TKIs induce acneiform rash and xerosis via Caspase-3/GSDME-mediated pyroptosis of keratinocytes and sebocytes.
Toxicology
November 2024
Department of Dermatology, Dermatology Hospital, Southern Medical University, No.2, Lujing Road, Yuexiu District, Guangzhou, Guangdong 510091, China. Electronic address:
Skin toxicities are the most common adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). While EGFR-TKIs induce pyroptosis in lung cancer cells through Gasdermin E (GSDME) activation, it is unknown whether they can similarly affect skin cells. In this study, we used immunohistochemistry to demonstrate that in acneiform rash, the N-terminus of GSDME (GSDME-N) is predominantly expressed in the basal layer of the follicular epithelium and sebocytes, while it is absent in the interfollicular epidermis.
View Article and Find Full Text PDFMucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.
Support Care Cancer
August 2024
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Article Synopsis
- MEK inhibitors often lead to mucocutaneous toxicities that can interfere with cancer treatment, prompting a review of related literature to understand these side effects better.
- The scoping review analyzed 227 relevant studies, revealing common toxicities like follicular reactions, ocular issues, dry skin, and eczema, with most cases being mild and manageable.
- Recognizing and addressing these side effects early on is crucial to minimizing interruptions in cancer therapy.
Folliculotropic Mycosis Fungoides In A Child: A Rare Case.
J Pak Med Assoc
November 2023
Department of Dermatology, PNS Shifa Hospital, Karachi, Pakistan.
Article Synopsis
- Folliculotropic mycosis fungoides (FMF) is a type of skin cancer that affects hair follicles, typically manifests as plaques and tumors, especially on the head and neck.
- It presents a variety of symptoms including prurigo-like lesions, cysts, and areas of scarring alopecia, with an average diagnosis age of 60 years, making it rare in younger people.
- A case study of a 12-year-old boy revealed an infiltrating plaque on his face that, upon biopsy, showed specific immune cell patterns confirming FMF diagnosis.
Follicular mycosis fungoides: Clinicohistopathologic features and outcomes in a series of 12 Chinese cases.
Indian J Dermatol Venereol Leprol
January 2024
Department of Dermatology, West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), Sichuan University, Chengdu, Sichuan, China.
Background Follicular mycosis fungoides is a distinct variant of mycosis fungoides with a broad clinical spectrum. Recently, many studies have indicated that follicular mycosis fungoides should be divided into different subtypes with disparate prognoses. Objective To define the clinicohistopathologic features and outcomes of follicular mycosis fungoides and to identify risk factors that may be related to the prognosis of Chinese patients with follicular mycosis fungoides.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!